Accelerating the Future...
- Award Categories: Human Development
- Award Year: 2019
- Nominee URL: https://www.designmedix.com/
Each year, there're 200 million cases of malaria and 4 billion cases of bacterial diarrhea, and these diseases cause over 3 million deaths worldwide. Malaria parasites and bacteria that cause these diseases are increasingly resistant to treatment with existing drugs.
DesignMedix has developed a proprietary approach to the rapid development of novel drug candidates to overcome drug resistance. This approach has resulted in a malaria drug in Phase I clinical trials at Duke Clinical Research Institute.
Our approach enables the rapid design and synthesis of novel drugs to enter the optimization stage of development far sooner than widely-used screening approaches. Development risk is reduced because the approach leverages safety and efficacy properties of the original drug.
The World Health Organization considers drug-resistance to be one of the top three threats to human health today. DesignMedix focuses on globally-important infectious diseases where additional drugs are urgently needed. DesignMedix's most advanced drug candidate, DM1157, is designed for the most vulnerable patients, pregnant women and children, for whom few drugs currently are available.